Ac Immune Sa · NASDAQ:ACIU
Ac Immune Sa — Shareholder Meeting (June 2017)
47 slides from Ac Immune Sa's shareholder meeting presentation, Jun 28, 2017
Slide 1: Novel Therapies and Diagnostics for Neurodegenerative Diseases with Focus on Alzheimer's
NOVEL THERAPIES AND DIAGNOSTICS FOR NEURODEGENERATIVE DISEASES WITH FOCUS ON ALZHEIMER’S www.acimmune.com Annual General Meeting | Lausanne | June 28, 2017 © 2017 AC Immune. Not to be used or reproduced without permission.
Slide 2: Disclaimer
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 2 Disclaimer This presentation may contain statements that constitute “forward - looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of
Slide 3: Highlights and achievements 2016/2017 – Company
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 3 Highlights and achievements 2016/2017 Company ▪ Entered research collaboration agreement with Essex Bio - Technology for development of novel biological therapeutic for the treatmen
Slide 4: Highlights and achievements – Clinical stage programs
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 4 Highlights and achievements Clinical stage programs Clinical stage programs ▪ Tau - PET imaging agent (1) : Published encouraging first clinical data from Phase 1 study with distinc
Slide 5: Highlights and achievements – Pre-clinical stage programs
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 5 Highlights and achievements Pre - clinical stage programs ▪ Morphomer Tau (AD): Lead candidates in late discovery stage showed inhibition of Tau aggregation, rescue of Tau induced t
Slide 6: Vision
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 6 Vision SupraAntigen TM Vaccines and antibodies specific to disease causing conformations Morphomer TM Conformation - sensitive small molecules Become a global leader in precision me
Slide 7: AC Immune – A leader in neurodegenerative diseases
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 7 AC Immune – A leader in neurodegenerative diseases Large and growing neurodegenerative disease market driven by significant unmet medical need 1 Multiple high - profile strategic al
Slide 8: AC Immune's technology leadership
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 8 AC Immune’s technology leadership Product - focused and highly productive platforms drive growth SupraAntigen TM Vaccines and antibodies specific to disease causing conformations Im
Slide 9: AC Immune's robust pipeline
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 9 (1) AD = Alzheimer’s disease (2) In process of completing a Phase 1/2a study (3) AD and cognitive impairment associated with Down syndrome ( 4) PET = positron emission tomography (5
Slide 10: Pillar strategy to create sustainable growth and long-term value
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 10 3 pillar strategy to create sustainable growth and long - term value Precision medicine as ultimate differentiation ▪ Develop best - in - class late stage assets in partnership ▪ D
Slide 11: Neurodegenerative diseases share MoA and targets
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 11 TDP - 43 α - synuclein Tau Abeta Neurodegenerative diseases share MoA and targets Additional value from leveraging therapies into neuro - orphan indications ▪ Parkinson’s disease ▪
Slide 12: AC Immune's robust clinical pipeline
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 12 AC Immune’s robust clinical pipeline
Slide 13: Crenezumab – Potentially transformative therapeutic, Phase 3
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 13 Crenezumab Potentially transformative therapeutic – Phase 3 Indication Alzheimer’s disease Target Misfolded Abeta Licensed to Key results in pre - clinical studies ▪ Unique epitope
Slide 14: Crenezumab – Binding characteristics and disaggregation mechanism
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 14 Crenezumab Compelling binding characteristics with unique disaggregation mechanism Crenezumab’s multiple neuroprotective mechanisms of action, in particular direct binding and inhi
Slide 15: Crenezumab – Uniquely differentiated profile with favorable safety
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 15 Crenezumab Uniquely differentiated profile with favorable safety * Reduced effector function, ** Full effector function; (1) Average of Expedition 1, 2 and 3 trials, (2) 10mg/kg do
Slide 16: Crenezumab – Phase 2 encouraging efficacy with favorable safety
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 16 Crenezumab Unique competitive position - Phase 2 - encouraging efficacy with favorable safety Efficacy ▪ 24 % and 35% reduction in primary endpoint ADAS - cog in ABBY mild patient
Slide 17: Crenezumab – Safety data and dose response simulations
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 17 Crenezumab Safety data and dose response simulations support Phase 3 dose of 60mg/kg This dose - response simulation of crenezumab is based on clinical trial simulations using the
Slide 18: Crenezumab – Ongoing key clinical studies
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 18 Crenezumab Ongoing key clinical studies Pivotal Phase 3 CREAD 1 and CREAD 2 efficacy and safety studies ▪ 300 cognitively healthy individuals who are expected to develop AD because
Slide 19: ACI-24 – Anti-Abeta therapeutic vaccine for AD, Phase 1/2a
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 19 ACI - 24 Anti - Abeta therapeutic vaccine for AD – Phase 1/ 2a Indication First: Alzheimer’s disease Target Misfolded Abeta Key results in pre - clinical studies ▪ Strong and robus
Slide 20: ACI-24 in DS – Anti-Abeta vaccine in Down syndrome, Phase 1b
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 20 ACI - 24 in DS Anti - Abeta therapeutic vaccine in Down syndrome – Phase 1b Indication Down syndrome (Trisomy 21) Target Misfolded Abeta Key results in pre - clinical studies ▪ Red
Slide 21: ACI-24 in DS – Phase 1b study overview
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 21 ACI - 24 in DS Phase 1b study overview Study design ▪ World first clinical trial for vaccine targeting Alzheimer’s disease in people with Down syndrome ▪ Randomized, placebo contro
Slide 22: Misfolded Tau as one major cause of neurodegeneration
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 22 Misfolded Tau as one major cause of neurodegeneration AC Immune’s Tau therapies intervene at key points in the disease pathway Healthy cell Affected cell Recipient cell Nucleus Mis
Slide 23: ACI-35 – Anti-pTau therapeutic vaccine for AD, Phase 1b
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 23 ACI - 35 Anti - pTau therapeutic vaccine for AD – Phase 1b Indication Alzheimer’s disease Target Aggregated pTau Key results in pre - clinical studies Development status ▪ Clinical
Slide 24: Anti-Tau antibody for AD – Phase 1
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 24 ▪ Dose - dependent reduction of Tau pathology ▪ Proven target engagement through dose - dependent rise of plasma Tau (mice, cynos ) ▪ Favorable safety and pharmacokinetic profile i
Slide 25: AC Immune diagnostics
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 25 AC Immune diagnostics Creation of precision medicine in neurodegenerative diseases Strategic value for AC Immune ▪ Enable early and better diagnosis of patients ▪ Improved selectio
Slide 26: Tau-PET imaging agent (PI-2620) – Phase 1
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 26 Tau - PET imaging agent (PI - 2620) Morphomer Tau for AD and PSP diagnostics – Phase 1 Indication Alzheimer’s disease and Progressive Supranuclear Palsy (PSP) Target Misfolded Tau
Slide 27: Financial overview
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 27 Financial overview
Slide 28: Financial overview (IFRS) – Key financial data, income statement
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 28 Financial overview (IFRS) Key financial data For the Year Ended December 31 (all figures in CHF millions excepts EPS data) 2016 2015 Change Income statement Revenues 23.2 39.1 (16.
Slide 29: Financial overview (IFRS) – Key financial data, balance sheet
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 29 Financial overview (IFRS) Key financial data As of December 31, (all figures in CHF millions) 2016 2015 Balance Sheet Cash and cash equivalents 152.2 76.5 Total current assets 154.
Slide 30: Catalyst timelines
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 30 Catalyst timelines
Slide 31: Near term value drivers
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 31 Near term value drivers ▪ ACI - 24 in AD ▪ Phase 2 expected to commence in 2017 ▪ ACI - 35 ▪ Next phase of clinical development based on Phase 1b data expected to commence in 2017
Slide 32: Strategy for value creation
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 32 Strategy for value creation EVOLVE strategy to develop late stage assets in - house CONTINUE to leverage our dual platform technologies to efficiently advance commercially viable p
Slide 33: Agenda items and proposals of the Board of Directors
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 33 Agenda items and proposals of the Board of Directors
Slide 34: Agenda
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 34 Agenda 1. Approval of the annual r eport , annual s tatutory f inancial s tatements and financial s tatements under IFRS of AC Immune SA for the year 2016 2. Appropriation of loss
Slide 35: Approval of the Annual Report and Financial Statements
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 35 Agenda item 1 ▪ The Board proposes to approve the A nnual R eport , the A nnual S tatutory F inancial Statements and the F inancial S tatements under IFRS of AC Immune SA for the y
Slide 36: Appropriation of Loss
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 36 Agenda item 2 ▪ The Board of Directors proposes that the net loss of the year 2016 in the amount of KCHF 7’628 is added to the loss brought forward of KCHF 24’930 resulting in a re
Slide 37: Discharge of the Members of the Board and the Executive Committee
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 37 Agenda item 3 ▪ The Board proposes that the members of the Board and the Executive Committee are discharged from their liabilities for their activities in the financial year 2016.
Slide 38: Compensation – Non-performance-related compensation for Board
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 38 Agenda item 4 ▪ The Board of Directors proposes to hold the following separate votes on the non - performance - related and the variable compensation of the Board of Directors and
Slide 39: Compensation – Equity for Members of the Board
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 39 Agenda item 4 ▪ The Board of Directors proposes to hold the following separate votes on the non - performance - related and the variable compensation of the Board of Directors and
Slide 40: Compensation – Non-performance-related compensation for Executive Committee
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 40 Agenda item 4 ▪ The Board of Directors proposes to hold the following separate votes on the non - performance - related and the variable compensation of the Board of Directors and
Slide 41: Compensation – Variable compensation for Executive Committee
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 41 Agenda item 4 ▪ The Board of Directors proposes to hold the following separate votes on the non - performance - related and the variable compensation of the Board of Directors and
Slide 42: Compensation – Equity for Executive Committee
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 42 Agenda item 4 ▪ The Board of Directors proposes to hold the following separate votes on the non - performance - related and the variable compensation of the Board of Directors and
Slide 43: Election of the Members of the Board
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 43 Agenda item 5 ▪ The Board of Directors proposes the re - election of Martin Velasco as member and as Chairman of the Board, Peter Bollmann , Friedrich von Bohlen, Andrea Pfeifer, D
Slide 44: Election to the Compensation, Nomination & Corporate Governance Committee
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 44 Agenda item 6 ▪ The Board of Directors proposes the re - election of Detlev Riesner , Martin Velasco and Tom Graney as members of the Compensation, Nomination & Corporate Governanc
Slide 45: Re-election of the independent proxy
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 45 Agenda item 7 ▪ The Board of Directors proposes that Bugnion Ballansat Ehrler , represented by Gérald Virieux , avocat , rue de Rive 6, case postale 3143, CH - 1211 Geneva 3 shall
Slide 46: Re-election of the Auditors
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 46 Agenda item 8 ▪ The Board of Directors proposes to re - elect Ernst & Young SA, in Lancy , for a term of office of one year. Re - election of the Auditors
Slide 47: Thank you for coming and your continued support
© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 47 We thank you for coming and your continued support.